Esprinet H1 2026 slides: strong growth drives guidance raise

Esprinet reported H1 2026 gross sales of €2.09B, up 8% year over year, while adjusted EBITDA rose 27% to €31.9M and adjusted EBIT increased 56% to €20.1M. The company raised full-year adjusted EBITDA guidance to €77M-€82M, supported by demand for AI, infrastructure, memory/storage, services and green technology. Zeliatech revenue grew 38% and Spain grew 21%, although higher inventory and receivables lifted operating working capital to €427.8M; net debt improved sequentially to €325.5M from €350.4M in Q1.

Analysis

The key underwriting issue is not the raised EBITDA range but the back-half burden it creates: H2 must generate roughly €45-50m of adjusted EBITDA versus €31.9m in H1. Seasonal Q4 volume can support that outcome, but the margin of safety is narrow for a distributor whose earnings are highly sensitive to product mix, vendor rebates, component pricing, and credit costs. The market should value the guidance upgrade only if Q3 demonstrates that higher-value infrastructure and services mix—not scarcity-driven pass-through pricing—is sustaining incremental margins.

PRT’s strongest structural asset is the mix shift toward V-Valley-like services and green-tech distribution, where gross-profit durability and customer switching costs are materially better than in commodity endpoint hardware. The second-order downside is that memory and storage shortages inflate both nominal sales and inventory funding needs; if supply normalizes before inventory is cleared, gross-margin gains can reverse while working capital remains elevated. Greater use of receivables factoring also reduces reported funding pressure but makes the equity more exposed to financing-market conditions and reseller credit deterioration.

Consensus may be underestimating the quality-of-earnings discount warranted by low ROCE and the capital intensity of growth. A guidance beat could drive a rerating over 1-3 months because the stock is near its highs, but a Q3 inventory build, weaker cash conversion, or even modest gross-margin erosion would likely matter more than revenue growth. Over 6-18 months, the investable thesis depends on converting the higher-margin divisions from a growth narrative into a sustained increase in group ROCE and free-cash-flow conversion.

Key Decisions for Investors

• Do not chase PRT immediately after the guidance revision; use Q3 results as the entry gate. Initiate a small long only if adjusted EBITDA run-rate supports the €77-82m range and inventory-to-sales declines sequentially; target a 15-20% upside rerating, with a 8-10% stop or exit on gross-margin contraction.
• For a relative-value expression, consider long PRT / short Bechtle (BC8) in equal euro beta only after confirming adequate PRT liquidity. The thesis is that PRT’s services/green-tech mix can close part of its quality discount; exit if PRT’s cash-conversion cycle fails to improve or BC8 guides materially above expectations.
• Treat reported sales growth as a low-quality signal during component shortages. Set a Q4 alert for inventory reduction and stable factoring usage: a meaningful inventory drawdown without a gross-profit-margin giveback would validate cash generation and support increasing exposure.
• Key falsifiers over the next 1-3 months: guidance reduction, a sequential increase in working-capital intensity, worsening reseller receivables, or gross margin below the H1 level. Any of these would shift the setup from a momentum long to a potential short/watchlist candidate, given the operating leverage embedded in a thin-margin distribution model.